Prostate Cancer Care Declined During the COVID-19 Pandemic
How the decline in health care visits will affect prostate cancer outcomes still needs to be determined.
How the decline in health care visits will affect prostate cancer outcomes still needs to be determined.
Compared with absolute PSA, PSA velocity associated more with increased likelihood of progression among men on active surveillance for prostate cancer.
Compared with no ureteroscopy or percutaneous biopsy, ureteroscopic biopsy in patients with upper tract urothelial carcinoma was significantly associated with a 40% increased risk for intravesical recurrence of disease.
Salvage cryotherapy is emerging as a viable local treatment option for prostate cancer that recurs following radiation treatment.
Investigators compared the efficacy, safety, and costs of abiraterone, darolutamide, enzalutamide, and apalutamide in treating nmCRPC.
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
Primary focal and radiation therapy for prostate cancer are associated with different rates of perioperative complications and long-term urinary continence recovery.
In a study, 1 in 4 male veterans with prostate cancer failed to receive a comprehensive assessment of their cardiovascular risk factors.